---
figid: PMC5593674__oncotarget-08-57654-g006
figtitle: 'Targeted therapies for gastric cancer: failures and hopes from clinical
  trials'
organisms:
- Homo sapiens
- Mus musculus
- mixed subtypes
organisms_ner:
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC5593674
filename: oncotarget-08-57654-g006.jpg
figlink: /pmc/articles/PMC5593674/figure/F6/
number: F6
caption: Schematic illustration of molecules expressed in tumor cells (left part)
  and T lymphocytes (right part) involved in the immune checkpoint inhibitory pathway
  and of the targeted drugs (the PD-1 mAbs Pembrolizumab and Nivolumab, the CTLA-4
  mAb Ipilimumab). The insert table shows the major trials targeting this pathway.
papertitle: 'Targeted therapies for gastric cancer: failures and hopes from clinical
  trials.'
reftext: Maria Apicella, et al. Oncotarget. 2017 Aug 22;8(34):57654-57669.
year: '2017'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8910446
figid_alias: PMC5593674__F6
figtype: Figure
redirect_from: /figures/PMC5593674__F6
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5593674__oncotarget-08-57654-g006.html
  '@type': Dataset
  description: Schematic illustration of molecules expressed in tumor cells (left
    part) and T lymphocytes (right part) involved in the immune checkpoint inhibitory
    pathway and of the targeted drugs (the PD-1 mAbs Pembrolizumab and Nivolumab,
    the CTLA-4 mAb Ipilimumab). The insert table shows the major trials targeting
    this pathway.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Ctla4
  - Pdcd1
  - Pdcd1lg2
  - Cd274
  - Tria1
  - Erbb2
  - HLA-C
  - CTLA4
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - PDCD1LG2
  - CD274
  - IP6K1
  - IP6K2
  - ERBB2
  - Mhc
  - zip
  - as
  - plu
  - Paclitaxel
---
